INTRODUCTION: Sphingomonas paucimobilis is ubiquitous in nature and widely found in soil, water resources, and hospital environments. Sphingomonas paucimobilis is mostly associated with nosocomial infection in immunocompromised patients. Various studies showed that diabetes mellitus, alcoholism, and malignancy are significant risk factors for S. paucimobilis infection. OBJECTIVES The present study aimed to determine the clinical spectrum of Sphingomonas paucimobilis with its associated risk factors and antimicrobial susceptibility pattern. MATERIAL AND METHODS: In the present study, clinical and microbiological profile of Sphingomonas paucimobilis isolated from various samples collected between July 2021 to August 2023 were considered. RESULTS: The present study was conducted between July 2021 to August 2023 in which Sphingomonas paucimobilis was isolated in 40 patients. Out of 40 patients, 26 were male and 14 were female. Out of 40,20 patients belonged to age group more than 60 years. Our study analysis showed that , diabetes mellitus ( odds ratio 0.3, 95% Confidence interval 0.239-0.839, p value= 0.0001), alcoholism ( odds ratio 4.4, 95% CI 1.283-15.396, p value= 0.011324) , prematurity( odds ratio 16.07, 95% CI 1.994-129.5, p value = 0.001965) and chronic lung disease ( odds ratio 2.80, 95% CI 1.1942-6.591, p = 0.0289) are significant risk factors for S paucimobilis infection. The organism showed 75% sensitivity to Cefepime,70% sensitivity to Amikacin, Meropenem, Ceftriaxone and Cefoperazone/sulbactam. CONCLUSION: S. paucimobilis is an emerging pathogen of clinical importance in both immunocompromised as well as immunocompetent host.. The major risk factors include diabetes, chronic lung disease, long-term steroid usage, and prematurity in newborns